Search Results - "Guerrera, L"

MYD88 wild‐type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival by Treon, Steven P., Gustine, Joshua, Xu, Lian, Manning, Robert J., Tsakmaklis, Nicholas, Demos, Maria, Meid, Kirsten, Guerrera, Maria L., Munshi, Manit, Chan, Gloria, Chen, Jiaji, Kofides, Amanda, Patterson, Christopher J., Yang, Guang, Liu, Xia, Severns, Patricia, Dubeau, Toni, Hunter, Zachary R., Castillo, Jorge J.

“…Summary MYD88 mutations are present in 95% of Waldenstrom Macroglobulinaemia (WM) patients, and support diagnostic discrimination from other IgM‐secreting…”
Get full text

Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials by Castillo, Jorge J., Gustine, Joshua N., Meid, Kirsten, Flynn, Catherine A., Demos, Maria G., Guerrera, Maria L., Jimenez, Cristina, Kofides, Amanda, Liu, Xia, Munshi, Manit, Tsakmaklis, Nicholas, Patterson, Christopher J., Xu, Lian, Yang, Guang, Hunter, Zachary R., Treon, Steven P.

“…Ibrutinib is the first approved therapy for symptomatic patients with Waldenström macroglobulinemia (WM). The approval was based on a single, multicenter,…”
Get full text

Venetoclax in Previously Treated Waldenström Macroglobulinemia by Castillo, Jorge J, Allan, John N, Siddiqi, Tanya, Advani, Ranjana H, Meid, Kirsten, Leventoff, Carly, White, Timothy P, Flynn, Catherine A, Sarosiek, Shayna, Branagan, Andrew R, Demos, Maria G, Guerrera, Maria L, Kofides, Amanda, Liu, Xia, Munshi, Manit, Tsakmaklis, Nicholas, Xu, Lian, Yang, Guang, Patterson, Christopher J, Hunter, Zachary R, Davids, Matthew S, Furman, Richard R, Treon, Steven P

“…BCL2 is overexpressed and confers prosurvival signaling in malignant lymphoplasmacytic cells in Waldenström macroglobulinemia (WM). Venetoclax is a potent BCL2…”
Get full text

CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib by Castillo, Jorge J., Xu, Lian, Gustine, Joshua N., Keezer, Andrew, Meid, Kirsten, Dubeau, Toni E., Liu, Xia, Demos, Maria G., Kofides, Amanda, Tsakmaklis, Nicholas, Chen, Jiaji G., Munshi, Manit, Guerrera, Maria L., Chan, Gloria G., Patterson, Christopher J., Yang, Guang, Hunter, Zachary R., Treon, Steven P.

“…Summary Ibrutinib is associated with response rate of 90% and median progression‐free survival (PFS) in excess of 5 years in Waldenström macroglobulinaemia…”
Get full text

Straightforward Synthesis of Sphinganines via a Serine-derived Weinreb Amide by So, Regina C, Ndonye, Rachel, Izmirian, Douglas P, Richardson, Stewart K, Guerrera, Robyn L, Howell, Amy R

“…Sphinganines can be synthesized in just three steps from easily prepared serine-derived Weinreb amide 4. Pre-deprotonation of the acidic (N−H and O−H) protons…”
Get full text

Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia by Castillo, Jorge J., Meid, Kirsten, Gustine, Joshua N., Leventoff, Carly, White, Timothy, Flynn, Catherine A., Sarosiek, Shayna, Demos, Maria G., Guerrera, Maria L., Kofides, Amanda, Liu, Xia, Munshi, Manit, Tsakmaklis, Nicholas, Xu, Lian, Yang, Guang, Branagan, Andrew R., O’Donnell, Elizabeth, Raje, Noopur, Yee, Andrew J., Patterson, Christopher J., Hunter, Zachary R., Treon, Steven P.

“…Herein, we present the final report of a single-center, prospective phase II study evaluating ibrutinib 420 mg once daily in 30 treatment-naive patients with…”
Get full text

Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next‐generation sequencing in Waldenström macroglobulinaemia by Gustine, Joshua N., Xu, Lian, Yang, Guang, Liu, Xia, Kofides, Amanda, Tsakmaklis, Nicholas, Munshi, Manit, Demos, Maria, Guerrera, Maria L., Meid, Kirsten, Patterson, Christopher J., Sarosiek, Shayna, Branagan, Andrew R., Hunter, Zachary R., Castillo, Jorge J., Treon, Steven P.

“…Summary CXCR4 mutations impact disease presentation and treatment outcomes in Waldenström macroglobulinaemia (WM). Non‐uniform testing for CXCR4 mutations may…”
Get full text

Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia by Castillo, Jorge J., Branagan, Andrew R., Sermer, David, Flynn, Catherine A., Meid, Kirsten, Little, Megan, Stockman, Katherine, White, Timothy, Canning, Alexa, Guerrera, Maria L., Kofides, Amanda, Liu, Shirong, Liu, Xia, Richardson, Kris, Tsakmaklis, Nicholas, Patterson, Christopher J., Hunter, Zachary R., Treon, Steven P., Sarosiek, Shayna

“…•The combination of ibrutinib and venetoclax induced deep and durable responses in treatment-naïve patients with Waldenström macroglobulinemia.•Planned study…”
Get full text

ERK1/2 pro‐survival signalling is suppressed by pirtobrutinib in ibrutinib‐resistant MYD88‐mutated lymphoma cells by Munshi, M., Liu, X., Kofides, A., Tsakmaklis, N., Hunter, Z. R., Guerrera, M. L., Canning, A., Gustine, J. N., Liu, S., Hatcher, J. M., Chen, J., Meid, K., Sarosiek, S., Flynn, C. A., Branagan, A. R., Keudell, G., Palomba, L. M., Castillo, J. J., Yang, G., Treon, S. P.

“…Summary Covalent Bruton's tyrosine kinase‐inhibitors (cBTK‐i) are highly active in MYD88‐mutated (MYD88Mut) Waldenstrom's macroglobulinaemia and suppress…”
Get full text

TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia by Gustine, Joshua N., Tsakmaklis, Nicholas, Demos, Maria G., Kofides, Amanda, Chen, Jiaji G., Liu, Xia, Munshi, Manit, Guerrera, Maria L., Chan, Gloria G., Patterson, Christopher J., Meid, Kirsten, Dubeau, Toni, Yang, Guang, Hunter, Zachary R., Treon, Steven P., Castillo, Jorge J., Xu, Lian

“…Summary Little is known about TP53 mutations in Waldenström Macroglobulinaemia (WM). We evaluated 265 WM patients for TP53 mutations by next‐generation…”
Get full text

Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia by Garcia-Sanz, Ramón, Varettoni, Marzia, Jiménez, Cristina, Ferrero, Simone, Poulain, Stephanie, San-Miguel, Jesus F., Guerrera, Maria L., Drandi, Daniela, Bagratuni, Tina, McMaster, Mary, Roccaro, Aldo M., Roos-Weil, Damien, Leiba, Merav, Li, Yong, Qiu, Luigi, Hou, Jian, De Larrea, C. Fernandez, Castillo, Jorge J., Dimopoulos, M., Owen, R.G., Treon, S.P., Hunter, Z.R.

“…Apart from the MYD88L265P mutation, extensive information exists on the molecular mechanisms in Waldenström's Macroglobulinemia and its potential utility in…”
Get full text

Partial response or better at six months is prognostic of superior progression‐free survival in Waldenström macroglobulinaemia patients treated with ibrutinib by Castillo, Jorge J., Abeykoon, Jithma P., Gustine, Joshua N., Zanwar, Saurabh, Mein, Kirsten, Flynn, Catherine A., Demos, Maria G., Guerrera, Maria L., Kofides, Amanda, Liu, Xia, Munshi, Manit, Tsakmaklis, Nickolas, King, Rebecca, Yang, Guang, Hunter, Zachary R., Advani, Ranjana H., Palomba, Maria Lia, Ansell, Stephen M., Gertz, Morie A., Kapoor, Prashant, Treon, Steven P.

“…Summary Ibrutinib is associated with durable responses in patients with Waldenström macroglobulinaemia (WM). We hypothesized that response depth is predictive…”
Get full text

CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors by Castillo, Jorge J., Gustine, Joshua N., Meid, Kirsten, Flynn, Catherine A., Demos, Maria G., Guerrera, Maria L., Jimenez, Cristina, Kofides, Amanda, Liu, Xia, Munshi, Manit, Tsakmaklis, Nicholas, Patterson, Christopher J., Xu, Lian, Yang, Guang, Hunter, Zachary R., Treon, Steven P.

Get full text

A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia by Castillo, Jorge J., Itchaki, Gilad, Gustine, Joshua N., Meid, Kirsten, Flynn, Catherine A., Demos, Maria G., Guerrera, Maria L., Jimenez, Cristina, Kofides, Amanda, Liu, Xia, Munshi, Manit, Tsakmaklis, Nicholas, Patterson, Christopher J., Xu, Lian, Yang, Guang, Hunter, Zachary R., Treon, Steven P.

“…Cases of non-IgM lymphoplasmacytic lymphoma (LPL) are rare. We performed a case-control study comparing features and outcomes of 31 non-IgM LPL cases and 93…”
Get full text

Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up by Castillo, Jorge J., Meid, Kirsten, Flynn, Catherine A., Chen, Jiaji, Demos, Maria G., Guerrera, Maria L., Kofides, Amanda, Liu, Xia, Munshi, Manit, Tsakmaklis, Nicholas, Patterson, Christopher J., Yang, Guang, Hunter, Zachary, Treon, Steven P.

“…Proteasome inhibition is a standard of care for the primary treatment of patients with Waldenström macroglobulinemia (WM). We present the long-term follow-up…”
Get full text

Deepening of response after completing rituximab‐containing therapy in patients with Waldenstrom macroglobulinemia by Castillo, Jorge J., Gustine, Joshua N., Keezer, Andrew, Meid, Kirsten, Flynn, Catherine A., Dubeau, Toni E., Chan, Gloria, Chen, Jiaji, Demos, Maria G., Guerrera, Maria L., Jimenez, Cristina, Kofides, Amanda, Liu, Xia, Munshi, Manit, Tsakmaklis, Nicholas, Patterson, Christopher J., Xu, Lian, Yang, Guang, Hunter, Zachary R., Treon, Steven P.

“…Rituximab‐containing regimens are commonly used for frontline therapy in patients with symptomatic Waldenström macroglobulinemia (WM). We had observed that a…”
Get full text

Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy by Castillo, Jorge J., Sarosiek, Shayna R., Gustine, Joshua N., Flynn, Catherine A., Leventoff, Carly R., White, Timothy P., Meid, Kirsten, Guerrera, Maria L., Kofides, Amanda, Liu, Xia, Munshi, Manit, Tsakmaklis, Nicholas, Hunter, Zachary R., Patterson, Christopher J., Branagan, Andrew R., Treon, Steven P.

“…Bruton tyrosine kinase (BTK) inhibitors are the only FDA-approved treatments for Waldenström macroglobulinemia (WM). Factors prognostic of survival and…”
Get full text

247PPrognostic significance of progesterone receptor levels in luminal-like Her2- early breast cancer patients. A retrospective single cancer center analysis by Diana, A, Carlino, F, Franzese, E, Centonze, S, Guerrera, L P, Perrone, A, Vita, F De, Ciardiello, F, Orditura, M

“…Abstract Background The prognostic role of Progesterone receptor (PR) expression in early invasive breast cancer (BC) remains controversial. The aim of this…”
Get full text

P167 ECG ABNORMALITIES AND DOUBLE CORONARY FISTULA by Viele, A, Trivisonno, A, Porchetta, N, Guerrera, L, Giannotti, G, Cuzzola, B, Colavita, A

“…Abstract Coronary artery fistula (CAF) is defined as anomalous communication between coronary arteries and cardiac chamber or a major thoracic vessel. CAF are…”
Get full text

The use of a telematic connection for the follow-up of hypertensive patients improves the cardiovascular prognosis by De Luca, Nicola, Izzo, Raffaele, Iaccarino, Guido, Malini, Pier Luigi, Morisco, Carmine, Rozza, Francesco, Iovino, Gianni Luigi, Rao, Maria Assunta Elena, Bodenizza, Clara, Lanni, Francesca, Guerrera, Luigi, Arcucci, Oreste, Trimarco, Bruno

“…BACKGROUNDInadequate blood pressure (BP) control could be due to incorrect management of hypertensives caused by the lack of interaction between general…”
Get full text